Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03319940 · ClinicalTrials.gov registry record · Phase 1
Study Evaluating Safety, Tolerability and Pharmacokinetics (PK) of Tarlatamab in Adults With Small Cell Lung Cancer (SCLC)
A Phase 1 study of Small Cell Lung Carcinoma, sponsored by Amgen.
- Active
- Registry status
- Phase 1
- Development phase
- 269
- Enrollment target
- 20
- Study locations
NCT03319940 is a Phase 1 study of Small Cell Lung Carcinoma that is active but no longer recruiting, run by Amgen. The registered enrollment target is 269 participants, roughly in line with the 246-participant average among 18 other Small Cell Lung Carcinoma trials with a reported enrollment target. The trial reports 20 study locations across 15 states.
The verdict
NCT03319940, a Phase 1 study of Small Cell Lung Carcinoma, is active but no longer recruiting, sponsored by Amgen.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 1
- Development phase
- 269 participants
- Enrollment target
- 20
- Study locations
Study Summary
A study to assess the safety, tolerability, and PK of tarlatamab in participants with SCLC
Conditions Studied
Interventions
- DRUG Pembrolizumab
- DRUG Tarlatamab
- DRUG CRS Mitigation Strategies
Study Locations (20)
Other
- Medizinische Universitaet Graz - Graz
- Landeskrankenhaus Salzburg - Salzburg
- Gustave Roussy - Villejuif
- Universitaetsklinikum Wuerzburg - Würzburg
Ohio
- University Hospitals Cleveland Medical Center - Cleveland
- The Ohio State University Wexner Medical Center - Thoracic Oncology Clinic - Columbus
Pennsylvania
- Fox Chase Cancer Center - Philadelphia
- University of Pittsburgh Medical Center Cancer Pavillion - Pittsburgh
California
- City of Hope National Medical Center - Duarte
Connecticut
- Yale New Haven Hospital - New Haven
Florida
- Moffitt Cancer Center - Tampa
Georgia
- Winship Cancer Institute - Atlanta
Illinois
- University of Chicago - Chicago
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 269 participants |
| Start Date | 2017-12-26 |
| Est. Completion | 2027-12-31 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03319940
The ClinicalTrials.gov registry entry for NCT03319940 describes a study currently listed as active not recruiting, categorized as Phase 1. The registered enrollment target is 269 participants, a figure that helps gauge the scale of data the investigators plan to collect, roughly in line with the 246-participant average among 18 other Small Cell Lung Carcinoma trials with a reported enrollment target. The listed sponsor is Amgen, which has 558 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Small Cell Lung Carcinoma appearing as the primary indexed condition, and to 3 interventions - of which Pembrolizumab is the first listed.
NCT03319940 reports 20 study locations spanning 15 distinct geographic areas - top geographies include Other, Ohio, Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT03319940 about?
NCT03319940 is a clinical study titled "Study Evaluating Safety, Tolerability and Pharmacokinetics (PK) of Tarlatamab in Adults With Small Cell Lung Cancer (SCLC)". A study to assess the safety, tolerability, and PK of tarlatamab in participants with SCLC
What is the current status of trial NCT03319940?
This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 269 participants. The study started on 2017-12-26. Estimated completion is 2027-12-31.
What conditions does trial NCT03319940 study?
This clinical trial studies the following conditions: Small Cell Lung Carcinoma.
What interventions are being tested in trial NCT03319940?
The interventions under investigation include: Pembrolizumab (DRUG), Tarlatamab (DRUG), CRS Mitigation Strategies (DRUG).
Who is sponsoring clinical trial NCT03319940?
This trial is sponsored by Amgen, which has 558 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03319940 being conducted?
This trial has 20 study locations across California, Connecticut, Florida, Georgia, Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Small Cell Lung Carcinoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study of LY4175408 in Participants With Advanced Cancer
RECRUITING · Phase 1
-
PET/CT Imaging of Small Cell Lung Cancer Using 89Zr-DFO-SC16.56
RECRUITING · Phase 1
-
Small Cell Lung Cancer Irinotecan and CDC2-like Kinase Inhibition Trial (SLICK Trial)
RECRUITING · Phase 1
-
A Study of SGN-CEACAM5C in Adults With Advanced Solid Tumors
RECRUITING · Phase 1
-
Safety and Efficacy Study of Investigational Agents as Monotherapy or in Combination With Pembrolizumab (MK-3475) for the Treatment of Extensive-Stage Small Cell Lung Cancer (ES-SCLC) in Need of Second-Line Therapy (MK-3475-B98/KEYNOTE-B98)
RECRUITING · Phase 1
-
Phase I Study of [225Ac]Ac-ETN029 in Patients With Advanced DLL3-expressing Solid Tumors
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.